XTL Biopharmaceuticals Ltd.
PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS

Abstract:

The present invention provides a method of treating a human subject suffering from systemic lupus erythematosus (SLE) and having at least one organ system categorized by the British Isles Lupus Assessment Group 2004 ("BILAG") as category A ("BILAG A") or at least two organ systems categorized as BILAG B comprising periodic administration to the human subject of one subcutaneous injection of 0.25 mg dose of Edratide every week, so as to treat the human subject.